Page 6 - Patrick Barth News Today

FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in the

(2) FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizers investigational drug PF-06946860 Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to significant functional impairment and increased risk of death Successful cachexia treatment can potentially contribute to improved cancer treatment worldwi...

FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer's...

F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020 Group sales increase 1% 1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32% 2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER 3), but not t...

F. Hoffmann-La Roche Ltd: Roche renews partnership with Sysmex to deliver haematology testing solutions This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests 1 Basel...

(2) Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment Nearly half of people were treated with faricimab every 16 weeks during the first year - the first time this level of durability has been achieved in a phase III study of an injectable eye medicine for neovascular age-related macular degeneration Faricimab is the f...

French Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will take place on 16 March 2021 without the physical presence of shareholders and with only the persons required by the Articles of Incorporation in attendance During the Annual General Meeting, shareholders rights will be exercised exclusively via the independent proxy, without the physical presence of shareholders Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will n...

(2) Due to the pandemic, the Annual General Meeting of Roche Holding Ltd will take place on 16 March 2021 without the physical presence of shareholders and with only the persons required by the Articles of Incorporation in attendance During the Annual General Meeting, shareholders rights will be exercised exclusively via the independent proxy, without the physical presence of shareholders Basel, 18 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that unfortunately it will not ...

New agreement covers 1.25 million additional doses of the antibody cocktail, bringing the total potential US supply to over 1.5 million dosesCasirivimab...

F. Hoffmann-La Roche Ltd: Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer 19.2 6.9 18.1 Tecentriq + Avastin (n=133) 24.0 (0.35-0.80) Median follow-up: 15.6 months. CR, complete response; DOR, duration of response; HR, hazard ratio; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression free response; PR, partial response; SD, stable disease...